Apellis Pharmaceuticals, Inc. (APLS)

47.22 +1.17 (+2.54%) 市場開市。 截至 01:58PM EDT。

Apellis Pharmaceuticals, Inc.

100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700
https://www.apellis.com

版塊: Healthcare
行業: Biotechnology
全職員工: 702

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Cedric Francois M.D., Ph.D.	Co-Founder, President, CEO & Director	1.44M	35.28M	1972
Mr. Mark Jeffrey Delong	Chief Business & Strategy Officer	無	無	1977
Dr. Philip Ferrone M.D.	Chief Medical Retina Advisor	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

公司管治

截至 2024年5月1日 止，Apellis Pharmaceuticals, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：4；董事會：6；股東權利：8；現金賠償：4。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。